Dianthus Therapeutics, Inc. - Common Stock (NQ:DNTH)

78.55 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, Mar 24, 2026 Add to My Watchlist

Price and Volume

Volume	0
Open	78.55
Bid (Size)	45.00 (600)
Ask (Size)	99.88 (500)
Prev. Close	78.55
Today's Range	78.55 - 78.55
52wk Range	13.37 - 88.02
Shares Outstanding	60,648,883
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit ↗

March 18, 2026

Clinical-stage biotech Dianthus Therapeutics develops antibody therapies for severe autoimmune and neuromuscular conditions.

Via The Motley Fool

Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

March 12, 2026

From Dianthus Therapeutics, Inc.

Via GlobeNewswire

Performance

YTD	+98.0%	+98.0%
1 Month	+49.1%	+49.1%
3 Month	+84.3%	+84.3%
6 Month	+107.4%	+107.4%
1 Year	+304.7%	+304.7%

More News

Complementing the Future: A Deep Dive into Dianthus Therapeutics (DNTH) After Its Phase 3 Breakthrough

March 12, 2026

Via Finterra

Dianthus Therapeutics, Inc. Announces Pricing of Upsized $625 Million Underwritten Public Offering

March 10, 2026

From Dianthus Therapeutics, Inc.

Via GlobeNewswire

Dianthus Therapeutics, Inc. Announces Proposed $400 Million Underwritten Public Offering

March 09, 2026

From Dianthus Therapeutics, Inc.

Via GlobeNewswire

DNTH Stock Soars After Early ‘Go’ Decision For Drug In Autoimmune Disorder Program, Boosting Wall Street Optimism For Potential Launch ↗

March 09, 2026

Via Stocktwits

Gapping stocks in Monday's session ↗

March 09, 2026

Via Chartmill

Dianthus Therapeutics Highlights Recent Business Achievements, Including GO Decision for Phase 3 CAPTIVATE CIDP Trial, and Reports Q4 and FY 2025 Financial Results

March 09, 2026

From Dianthus Therapeutics, Inc.

Via GlobeNewswire

Dianthus Therapeutics Announces Early GO Decision Following Interim Responder Analysis in Phase 3 CAPTIVATE Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

March 09, 2026

From Dianthus Therapeutics, Inc.

Via GlobeNewswire

Dianthus Therapeutics to Host Conference Call and Webcast to Discuss the Interim Responder Analysis Results of the Phase 3 Captivate Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

March 08, 2026

From Dianthus Therapeutics, Inc.

Via GlobeNewswire

Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 03, 2026

From Dianthus Therapeutics, Inc.

Via GlobeNewswire

Dianthus Therapeutics to Participate in The TD Cowen 46th Annual Health Care Conference

February 24, 2026

From Dianthus Therapeutics, Inc.

Via GlobeNewswire

The Great Rotation: Small-Caps Break the Mega-Cap Monopoly in Early 2026

February 23, 2026

Via MarketMinute

Dianthus Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

February 05, 2026

From Dianthus Therapeutics, Inc.

Via GlobeNewswire

Dianthus CFO Sells 20,000 Shares for $903,600 After Massive Year-End Run ↗

January 07, 2026

Via The Motley Fool

Dianthus Therapeutics To Participate in the 44th Annual J.P. Morgan Healthcare Conference

January 05, 2026

From Dianthus Therapeutics, Inc.

Via GlobeNewswire

Leads Biolabs And Dianthus Therapeutics Announce Initiation of Phase 1 Trial Of LBL-047 (DNTH212) In Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE)

December 23, 2025

From Dianthus Therapeutics, Inc.

Via GlobeNewswire

Dianthus Therapeutics To Participate in the 8th Annual Evercore Healthcare Conference

November 24, 2025

From Dianthus Therapeutics, Inc.

Via GlobeNewswire

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results

November 05, 2025

From Dianthus Therapeutics, Inc.

Via GlobeNewswire

Dianthus Therapeutics to Participate in Four Investor Conferences During November

November 04, 2025

From Dianthus Therapeutics, Inc.

Via GlobeNewswire

Dianthus Therapeutics Highlights New Claseprubart Data Presented During 2025 AANEM Annual Meeting

October 29, 2025

From Dianthus Therapeutics, Inc.

Via GlobeNewswire

Dianthus Therapeutics Announces Exclusive License Agreement with Leads Biolabs for DNTH212, a First and Potentially Best-In-Class, Phase 1 Ready Bifunctional BDCA2 & BAFF/APRIL Inhibitor for Severe Autoimmune Diseases

October 16, 2025

From Dianthus Therapeutics, Inc.

Via GlobeNewswire

Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2025 AANEM Annual Meeting

October 02, 2025

From Dianthus Therapeutics, Inc.

Via GlobeNewswire

General Motors To Rally More Than 24%? Here Are 10 Top Analyst Forecasts For Friday ↗

September 12, 2025

Via Benzinga

3 Biotech Stocks Showing Strength With Big Spikes In Momentum Scores ↗

September 12, 2025

Via Benzinga

Frequently Asked Questions

Is Dianthus Therapeutics, Inc. - Common Stock publicly traded?

Yes, Dianthus Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Dianthus Therapeutics, Inc. - Common Stock trade on?

Dianthus Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Dianthus Therapeutics, Inc. - Common Stock?

The ticker symbol for Dianthus Therapeutics, Inc. - Common Stock is DNTH on the Nasdaq Stock Market

What is the current price of Dianthus Therapeutics, Inc. - Common Stock?

The current price of Dianthus Therapeutics, Inc. - Common Stock is 78.55

When was Dianthus Therapeutics, Inc. - Common Stock last traded?

The last trade of Dianthus Therapeutics, Inc. - Common Stock was at 03/24/26 04:00 PM ET

What is the market capitalization of Dianthus Therapeutics, Inc. - Common Stock?

The market capitalization of Dianthus Therapeutics, Inc. - Common Stock is 4.76B

How many shares of Dianthus Therapeutics, Inc. - Common Stock are outstanding?

Dianthus Therapeutics, Inc. - Common Stock has 5B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.